Printer Friendly

Hemostemix Announces Convertible Debenture Financing.

CALGARY, Alberta, Canada, April 15, 2019 -- Blood-derived stem cell therapy company Hemostemix Inc., (OTCQB: HMTXF) said that it intends to complete a non-brokered private placement of $6 million secured convertible debentures.

Each debenture will consist of $1,000 aggregate principal amount of 8 percent secured, non-transferable, convertible, redeemable debentures. The debentures will mature twenty-four months from the date of issuance with interest at eight percent a year.

The proceeds of the debenture offering will be used to continue to fund the company's phase 2 trial for CLI, research and development, costs towards other clinical trials including application for an angina pectoris trial and for general working capital.

Contact: http://www.hemostemix.com

COPYRIGHT 2019 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Finance & Funding
Publication:Stem Cell Business News
Date:Apr 29, 2019
Words:112
Previous Article:Osiris Acquisition By Smith & Nephew Plc Closes.
Next Article:ThermoGenesis Releases Enhanced X-MINI CD3 Selection Kit For Researchers.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters